LianBio SEC filings LIANY
LianBio has 170 filings in SEC EDGAR's recent list, going back to Nov 12, 2020. Its latest annual report, Form 10-K, was filed on Mar 28, 2023 for the period ended Dec 31, 2022. The latest quarterly report (Form 10-Q) was filed on Nov 13, 2023, covering the quarter ended Sep 30, 2023. The most recent current report (Form 8-K) was filed on Feb 13, 2024 (exit or restructuring costs, listing notice, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 19, 2023 | — |
| DEF 14A | Proxy statement | Apr 19, 2023 | Jun 21, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIANY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Princeton, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1831283
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.